Pagibaximab

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.[1][2]

Pagibaximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
Targetstaphylococcal lipoteichoic acid
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6462H9996N1728O2028S54
Molar mass146072.36 g·mol−1
 NY (what is this?)  (verify)

References
  1. Weisman, LE; Thackray, HM; Garcia-Prats, JA; Nesin, M; Schneider, JH; Fretz, J; Kokai-Kun, JF; Mond, JJ; Kramer, WG (2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial Agents and Chemotherapy. 53 (7): 2879–86. doi:10.1128/AAC.01565-08. PMC 2704668. PMID 19380597.
  2. Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.